A urinary DNA methylation test demonstrated high sensitivity and specificity for detecting high-grade or invasive bladder cancer, outperforming both nuclear matrix protein 22 (NMP22) and urine ...
The Decipher Bladder test identifies aggressive bladder cancer, aiding in treatment decisions beyond initial clinical staging. Non-luminal tumors in NMIBC show higher upstaging rates to MIBC and ...
Please provide your email address to receive an email when new articles are posted on . A urinary DNA methylation test outperformed the nuclear matrix protein 22 test or urine cytology test.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data that reinforce the ability of its Decipher Bladder ...
A noninvasive urinary DNA methylation test demonstrated high sensitivity for detecting high-grade or invasive bladder cancer. A urinary DNA methylation test displayed superior sensitivity for ...
New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...
A “game-changer” study claims bladder cancer patients given an immunotherapy drug are a third less likely to see disease come ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ...
Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback